Questions continue to be raised over the data reported to Open Payments, the Affordable Care Act policy that requires drug and device companies to annually report payments to physicians and teaching hospitals.
The 2015 data released in June showed $7.52 billion in payments to 620,000 physicians and 1,100 teaching hospitals. The American Medical Association and other industry groups say the data are not adequately checked.
Pharmaceutical, biotech and medical-device executives along with government officials will get to weigh in on the issue at a gathering this week in Washington.
CBI's 10th annual conference on transparency reporting will include as speakers Robin Usi and Erin Skinner of the CMS' Division of Data and Informatics and officials from the U.S. Justice Department. Employees of Bristol-Myers Squibb, AstraZeneca and Novo Nordisk are also on the agenda.
The first day of the conference will include a workshop that focuses on complying with the Open Payments program in medical device, supplies and dental manufacturing, as well as distribution. Another workshop will look at regulations for transparency reporting at meetings and events.
Discussion topics in the following days include recent trends in enforcement targets, future use of Open Payments data, what an Open Payments audit would look like and ways to improve communication with doctors.
Massachusetts-based CBI is a division of UBM Americas that hosts conferences for the life sciences industry.
